Company Filing History:
Years Active: 2018-2022
Title: Chin-Yu Lai: Innovator in Ophthalmic Formulations
Introduction
Chin-Yu Lai is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of ophthalmic formulations, particularly focusing on the development of innovative treatments for ocular surface diseases. With a total of 3 patents to his name, Lai's work is paving the way for advancements in eye care.
Latest Patents
Lai's latest patents include groundbreaking formulations that utilize tyrosine kinase inhibitors. One notable patent details ophthalmic formulations containing nintedanib, or a pharmaceutically acceptable salt thereof. These formulations can incorporate microparticles or nanoparticles of nintedanib, providing new methods for treating ocular surface diseases, such as dry eye disease. Another patent focuses on crystalline forms of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-phenylamino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone. This patent outlines the preparation methods and pharmaceutical formulations containing these crystalline forms, emphasizing their use in treating angiogenic eye diseases.
Career Highlights
Chin-Yu Lai is currently associated with Allgenesis Biotherapeutics Inc., where he continues to innovate in the field of biotherapeutics. His work is characterized by a commitment to improving patient outcomes through advanced pharmaceutical formulations.
Collaborations
Lai collaborates with talented professionals in his field, including Tan Nguyen and Fei Liu. These partnerships enhance the research and development efforts at Allgenesis Biotherapeutics Inc., fostering a collaborative environment for innovation.
Conclusion
Chin-Yu Lai's contributions to ophthalmic formulations demonstrate his dedication to advancing eye care through innovative solutions. His patents reflect a commitment to addressing critical health issues, making him a notable figure in the field of biotherapeutics.